Ozawa Shota, Matsubayashi Masaya, Nanaura Hitoki, Yanagita Motoko, Mori Kiyoshi, Asanuma Katsuhiko, Kajiwara Nobuyuki, Hayashi Kazuyuki, Ohashi Hiroshi, Kasahara Masato, Yokoi Hideki, Kataoka Hiroaki, Mori Eiichiro, Nakagawa Takahiko
TMK Project at the Medical Innovation Center, Kyoto University, Kyoto, Japan; Research Unit/Innovative Medical Science, Mitsubishi Tanabe Pharma Corporation, Saitama, Japan.
Department of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
J Biol Chem. 2020 Nov 20;295(47):16002-16012. doi: 10.1074/jbc.RA120.013721. Epub 2020 Sep 9.
Podocyte injury is a critical step toward the progression of renal disease and is often associated with a loss of slit diaphragm proteins, including Podocin. Although there is a possibility that the extracellular domain of these slit diaphragm proteins can be a target for a pathological proteolysis, the precise mechanism driving the phenomenon remains unknown. Here we show that Matriptase, a membrane-anchored protein, was activated at podocytes in CKD patients and mice, whereas Matriptase inhibitors slowed the progression of mouse kidney disease. The mechanism could be accounted for by an imbalance favoring Matriptase over its cognate inhibitor, hepatocyte growth factor activator inhibitor type 1 (HAI-1), because conditional depletion of HAI-1 in podocytes accelerated podocyte injury in mouse model. Matriptase was capable of cleaving Podocin, but such a reaction was blocked by either HAI-1 or dominant-negative Matriptase. Furthermore, the N terminus of Podocin, as a consequence of Matriptase cleavage of Podocin, translocated to nucleoli, suggesting that the N terminus of Podocin might be involved in the process of podocyte injury. Given these observations, we propose that the proteolytic cleavage of Podocin by Matriptase could potentially cause podocyte injury and that targeting Matriptase could be a novel therapeutic strategy for CKD patients.
足细胞损伤是肾病进展的关键步骤,并且常与包括Podocin在内的裂孔隔膜蛋白的丢失相关。尽管这些裂孔隔膜蛋白的细胞外结构域有可能成为病理性蛋白水解的靶点,但驱动该现象的精确机制仍不清楚。在此我们表明,Matriptase是一种膜锚定蛋白,在慢性肾病患者和小鼠的足细胞中被激活,而Matriptase抑制剂减缓了小鼠肾病的进展。该机制可以通过Matriptase与其同源抑制剂1型肝细胞生长因子激活抑制剂(HAI-1)之间的失衡来解释,因为在小鼠模型中足细胞中HAI-1的条件性缺失加速了足细胞损伤。Matriptase能够切割Podocin,但这种反应被HAI-1或显性负性Matriptase阻断。此外,由于Matriptase对Podocin的切割,Podocin的N末端易位至核仁,提示Podocin的N末端可能参与足细胞损伤过程。基于这些观察结果,我们提出Matriptase对Podocin的蛋白水解切割可能会导致足细胞损伤,并且靶向Matriptase可能是慢性肾病患者的一种新型治疗策略。